GlassScriptPhysician profile
Despina Siolas
NPI 1598083552
$8,027.19
in general payments reported to CMS, 2019-2025
19 companies · $3,119 in 2025
The $3,119 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $136 · 2021: $1,800 · 2022: $157 · 2023: $121 · 2024: $2,550 · 2025: $3,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,600 · Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,600.00 |
| Food and Beverage | $1,190.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,257.97 | 2022-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $1,933.77 | 2021-2025 | Keytruda, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $849.33 | 2024-2025 | Imfinzi |
| Genentech USA, INC. | $263.13 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $155.14 | 2024-2025 | Onivyde, Somatuline Depot |
| Tersera Therapeutics LLC | $94.94 | 2023-2024 | Xermelo |
| Novartis Pharmaceuticals Corporation | $74.65 | 2022-2025 | |
| Astellas Pharma US INC | $62.90 | 2025 | Vyloy |
| Pfizer INC. | $57.50 | 2025 | |
| Taiho Oncology, INC. | $52.18 | 2024-2025 | |
| Array Biopharma INC | $45.22 | 2025 | Braftovi, Tukysa |
| Abbvie INC. | $33.68 | 2023 | Creon |
| Jazz Pharmaceuticals INC. | $30.52 | 2024 | |
| Novocure INC. | $28.99 | 2022 | |
| Springworks Therapeutics, INC. | $27.20 | 2025 | Ogsiveo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $22.61 | 2024 | |
| Aadi Bioscience, INC. | $21.35 | 2023 | Fyarro |
| Regeneron Pharmaceuticals, INC. | $16.11 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Despina Siolas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.